Delisting Determination,The Nasdaq Stock Market, LLC,
November 24, 2015, BG Medicine, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the common stock of BG Medicine, Inc.
(the Company), effective at the opening of the trading
session on December 4, 2015. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rules 5550(a)(2) and 5550(b)(1).
The Company was notified
of the Staffs determination on March 10, 2015.  The
Company appealed the determination to a Hearing Panel.
Upon review of the information provided by the Company,
the Panel issued a decision dated April 28, 2015, granting
the Company continued listing pursuant to an exception
that included several milestones that the Company was
required to meet, towards the toal of regaining compliance
with Listing Rule 5550(a)(2) and 5550(b)(1). However, the
Company was
unable to meet the exception milestones as required.
On September 14, 2015, the Panel issued a final delisting
determination and notified the Company that trading in the Companys
securities would be suspended on September 16, 2015.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Company
became final on October 29, 2015.